Page 35 - Delaware Medical Journal - September/October 2020

TREATMENT
TABLE 1: PATIENT CHARACTERISTICS
CHARACTERISTIC NUMBER OF PATIENTS MEDIAN AGE (RANGE) RACE
Black
White
SEX
Male
Female
PET SCAN
SUV
SURGERY TYPE
Lobectomy
Wedge
SURGICAL APPROACH
Open
VATS
NODAL SAMPLING
Yes
No
HISTOLOGY
Adenocarcinoma
Squamous Cell
5 YR SURVIVAL STATUS
Alive
Dead
5 YR RECURRENCE STATUS
No Recurrence
Recurrence
5 YR RECURRENCE FREE SURVIVAL
No Event Event
INTRODUCTION
Lung cancer remains the most common cause of cancer mortality in the United remains poor at 23% due to the often advanced stage of disease at the time of diagnosis.1 However, early detection with annual low-dose CT scans can reduce cancer-related mortality by 20%.2 As lung-cancer screening
becomes more prevalent, smaller pulmonary nodules are being detected. However, distinguishing what is at sub-centimeter sizes. Imaging tests are less accurate and invasive tests are associated with additional costs and possible unnecessary complications. An unanswered question is how aggressively we should pursue lung cancers less
than 1cm in size. To help answer this,
GROUP 3 (10MM)
22
64.5 (41-80)
2 (9.09%) 20 (90.9%)
9 (40.9%) 13 (59.1%) 8/12
6/8
4 (18.2%) 18 (81.8%)
11 (50.0%) 11 (50.0%)
8 (36.4%) 14 (63.6%)
16 (68.2%) 6 (37.5%)
16 (72.7%) 6 (27.3%)
14 (63.6%) 8 (36.4%)
14 (63.6%) 8 (36.4%)
we investigated the characteristics
and outcomes of sub-centimeter lung cancers being detected at the Helen
F. Graham Cancer Center & Research Institute at ChristianaCare. We have also collaborated with the Wistar Institute Cancer Center in developing a peripheral blood test that will detect malignancy in sub-centimeter nodules. This information will help guide the management of small lung cancers.
GROUP 1 (5-7MM)
GROUP 2 (8-9MM)
11
12
66 (35-77)
67 (54-77)
2 (18.2%)
1 (8.33%)
9 (81.8%)
11 (91.7%)
2 (18.2%)
8 (66.7%)
9 (81.8%)
4 (33.3%)
4/11
4/12
1/4
0/4
4 (36.3%)
6 (50.0%)
7 (63.6%)
6 (50.0%)
5 (45.5%)
5 (41.7%)
6 (54.5%)
7 (58.3%)
4 (36.4%)
5 (41.7%)
7 (63.6%)
7 (58.3%)
11 (100%)
9 (75.0%)
0 (0.00%)
3 (25.0%)
8 (72.7%)
9 (75.0%)
3 (27.3%)
3 (25.0%)
8 (72.7%)
10 (83.3%)
3 (27.3 %)
2 (16.7%)
7 (63.6%)
8 (66.7%)
4 (36.4%)
4 (33.3%)
Del Med J | September/October 2020 | Vol. 92 | No. 5
227